Loading...
XASXPIQ
Market cap59mUSD
Jan 08, Last price  
0.73AUD
1D
-1.36%
1Q
-8.23%
Jan 2017
208.51%
IPO
229.55%
Name

Proteomics International Laboratories Ltd

Chart & Performance

D1W1MN
XASX:PIQ chart
P/E
—
P/S
106.46
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
9.40%
Rev. gr., 5y
-9.48%
Revenues
892k
+22.15%
1,321,3331,128,082608,394816,845925,3571,176,4571,468,0761,423,0701,310,8241,489,323730,340892,143
Net income
-6m
L+2.28%
-251,319-246,527-1,149,202-1,328,456-916,475-1,440,108-2,080,275-1,743,770-2,859,663-4,972,960-6,234,310-6,376,219
CFO
-6m
L-1.75%
0-325,718-677,263-1,509,254-1,470,852-1,083,877-1,667,009-384,508-2,209,073-3,539,963-5,692,911-5,593,147
Earnings
Feb 21, 2025

Profile

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.
URL
https://www.proteomics.com.au/
IPO date
Apr 16, 2015
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
892
22.15%
730
-50.96%
1,489
13.62%
Cost of revenue
13,845
9,532
8,443
Unusual Expense (Income)
NOPBT
(12,953)
(8,801)
(6,954)
NOPBT Margin
Operating Taxes
(2,156)
(148)
1,943
Tax Rate
NOPAT
(10,796)
(8,653)
(8,897)
Net income
(6,376)
2.28%
(6,234)
25.36%
(4,973)
73.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,629
10,839
245
BB yield
-5.99%
-10.82%
-0.25%
Debt
Debt current
95
31
(356)
Long-term debt
537
98
Deferred revenue
379
582
134
Other long-term liabilities
121
33
167
Net debt
(6,007)
(5,899)
(2,467)
Cash flow
Cash from operating activities
(5,593)
(5,693)
(3,540)
CAPEX
(403)
(1,218)
(129)
Cash from investing activities
(388)
(1,165)
(129)
Cash from financing activities
6,594
10,774
176
FCF
(11,186)
(10,521)
(7,779)
Balance
Cash
6,640
6,027
2,112
Long term investments
Excess cash
6,596
5,991
2,037
Stockholders' equity
9,249
8,323
3,394
Invested Capital
3,470
3,012
1,301
ROIC
ROCE
EV
Common stock shares outstanding
125,849
116,454
105,531
Price
0.88
2.33%
0.86
-7.53%
0.93
 
Market cap
110,747
10.58%
100,150
2.04%
98,144
 
EV
104,576
94,193
95,677
EBITDA
(12,225)
(8,272)
(6,537)
EV/EBITDA
Interest
23
446
Interest/NOPBT